---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-145668"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:47:19.720687+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus sells wound business to LifeNet Health for up to $85M

## Summary
- Total cash consideration up to $85M: $35M at close, $5M deferred, $45M earn-out.
- Net proceeds ~$30M after fees and expenses will be used to repay existing debt.
- Divestiture reduces annual revenue by ~$40M and annual adjusted EBITDA by ~$5M.
- Transaction expected to close ~1 week before end of May 2023.
- Sales Agent Agreement grants LifeNet Health exclusive rights to sell SonicOne in US and Canada.

## SEC filing metadata
- accession: 0001193125-23-145668
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000119312523145668/0001193125-23-145668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000119312523145668/d466754d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-145668
- JSON: https://secwatch.observer/filing/0001193125-23-145668.json
- Plain text: https://secwatch.observer/filing/0001193125-23-145668.txt

## Key facts
- Material Agreements
  Bioventus Inc. entered into Asset Purchase Agreement with LifeNet Health valued at $35,000,000 (effective 2023-05-10).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: LifeNet Health
  - Value: $35,000,000
  - Effective: 2023-05-10
  source text: On May 10, 2023, Bioventus LLC (“BV LLC”), a subsidiary of Bioventus Inc. (the “Company”), together with two of its subsidiaries, Misonix, LLC (“Misonix”) and Solsys Medical, LLC (“Solsys,” and together with BV LLC and Misonix, the “Sellers”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with LifeNet Health (the “Buyer”), pursuant to which the Buyer agreed to: (i) acquire all assets of the Sellers related to the Sellers’ business of developing, marketing and distributing the TheraSkin Product and the TheraGenesis Product
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000119312523145668/0001193125-23-145668-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.